Home
  • About Exelixis
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Strategic Alliances
    • Locations
    • Contact Us
  • Cabozantinib
    • Clinical Trial Information
    • Bone Metastases
    • Preclinical Rationale and Results
    • Frequently Asked Questions
  • Pipeline
    • Cabozantinib (XL184)
    • Out-Licensed Compounds
    • Partnering Compounds
  • Investors
    • Management and Board
    • Corporate Governance
    • Stock Information
    • Analyst Coverage
    • Earnings Estimates
    • Earnings Ratings
    • Annual Reports
    • SEC Filings
    • Press Releases
    • Non-GAAP Financial Measures
    • Event Calendar
    • Information Request
    • Investor FAQs
    • Contact IR
  • Resources
    • Events
    • ASCO 2011 Online Summit
    • CEO Topic
    • Data Presentations
  • Careers
    • Job Opportunities
    • Benefits
    • Events
    • Awards
  • Contact Us

Investors

  • Management and Board
  • Corporate Governance
  • Stock Information
  • Analyst Coverage
  • Earnings Estimates
  • Earnings Ratings
  • Annual Reports
  • SEC Filings
  • Press Releases
  • Non-GAAP Financial Measures
  • Event Calendar
  • Information Request
  • Investor FAQs
  • Contact IR
© Exelixis, Inc. 2012   Website design: Hane Chow, Inc.
  • Terms of Use